9.44
0.05 (0.53%)
| Previous Close | 9.39 |
| Open | 9.48 |
| Volume | 853,237 |
| Avg. Volume (3M) | 1,625,224 |
| Market Cap | 2,964,905,728 |
| Price / Earnings (TTM) | 944.00 |
| Price / Sales | 1.11 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2025 |
| Profit Margin | -0.46% |
| Operating Margin (TTM) | 14.51% |
| Diluted EPS (TTM) | -0.040 |
| Quarterly Revenue Growth (YOY) | 5.50% |
| Quarterly Earnings Growth (YOY) | -49.70% |
| Current Ratio (MRQ) | 1.40 |
| Operating Cash Flow (TTM) | 306.92 M |
| Levered Free Cash Flow (TTM) | 311.48 M |
| Return on Assets (TTM) | 6.67% |
| Return on Equity (TTM) | -881.26% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | Amneal Pharmaceuticals, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 4.0 |
| Average | 2.25 |
|
Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products, Specialty products, and AvKARE. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, and the Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 46.75% |
| % Held by Institutions | 43.76% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Tpg Gp A, Llc | 30 Jun 2025 | 12,328,767 |
| Blackbarn Capital Partners Lp | 30 Jun 2025 | 3,446,570 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 11 Sep 2025 | Announcement | Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution |
| 04 Sep 2025 | Announcement | Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension |
| 05 Aug 2025 | Announcement | Amneal Reports Second Quarter 2025 Financial Results |
| 21 Jul 2025 | Announcement | Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032 |
| 21 Jul 2025 | Announcement | Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results |
| 09 Jul 2025 | Announcement | Amneal to Report Second Quarter 2025 Results on August 5, 2025 |
| 25 Jun 2025 | Announcement | Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |